抗高血脂药瑞舒伐他汀专利现状分析  

Analysis on Current Situation of the Patent of Rosuvastatin

作　　者：张欢[1] 牛蒙蒙 于培明[1] 

机构地区：[1]河南大学药学院,开封475004

出　　处：《中国药事》2015年第7期702-706,共5页Chinese Pharmaceutical Affairs

摘　　要：目的:介绍瑞舒伐他汀在中国的专利概况,为制药企业制定发展战略提供参考。方法:统计2000年至2013年间瑞舒伐他汀在中国的专利申请状况,包括申请量和授权量、申请区域、申请人、法律状态、专利内容等,并进行定量、定性分析。结果与结论:瑞舒伐他汀在我国尚无核心化合物专利,有效专利也不多,我国制药企业应争取拥有核心化合物专利,并尽快申请外围专利,形成多方位的专利保护网,促进民族医药产业的发展。Objective： To introduce the patent situation of Rosuvastatin in China and provide references for development of domestic pharmaceutical enterprises. Methods： The situation of patent application of Rosuvastatin in China, such as the numbers of application and approval, application distribution, applicants, legal status, patent contents, etc., from 2000 to 2013 was statistically studied through quantitative and qualitative analysis. Results and Conclusion： The patents of essential Rosuvastatin compounds do not exist in China at present, and the available patents are few. Therefore, the pharmaceutical enterprises of China should make efforts to obtain the patents of relevant essential compounds and apply for the peripheral patents as soon as possible to build the patent protection network and promote development of the national pharmaceutical industry.

关 键 词：抗高血脂药 瑞舒伐他汀 专利申请 专利授权 核心化合物 

分 类 号：R95[医药卫生—药学]